Authors:
MARINELLI M
BARROT M
SIMON H
OBERLANDER C
DEKEYNE A
LEMOAL M
PIAZZA PV
Citation: M. Marinelli et al., PHARMACOLOGICAL STIMULI DECREASING NUCLEUS-ACCUMBENS DOPAMINE CAN ACTAS POSITIVE REINFORCERS BUT HAVE A LOW ADDICTIVE POTENTIAL, European journal of neuroscience, 10(10), 1998, pp. 3269-3275
Citation: Mj. Millan et al., SEROTONIN (5-HT)(2C) RECEPTORS TONICALLY INHIBIT DOPAMINE (DA) AND NORADRENALINE (NA), BUT NOT 5-HT, RELEASE IN THE FRONTAL-CORTEX IN-VIVO, Neuropharmacology, 37(7), 1998, pp. 953-955
Authors:
MILLAN MJ
NEWMANTANCREDI A
BROCCO N
GOBERT A
LEJEUNE F
AUDINOT V
RIVET JM
SCHREIBER R
DEKEYNE A
SPEDDING M
NICOLAS JP
PEGLION JL
Citation: Mj. Millan et al., S-18126 4-(2,3-DIHYDROBENZO[1,4]DIOXIN-6-YL)PIPERAZIN-1-YL METHYL]INDAN-2-YL)), A POTENT, SELECTIVE AND COMPETITIVE ANTAGONIST AT DOPAMINE D-4 RECEPTORS - AN IN-VITRO AND IN-VIVO COMPARISON WITH L-745,870 YL]PIPERAZIN-1-YL)METHYL-1H-PYRROLO[2,3B]PYRIDINE) AND RACLOPRIDE, The Journal of pharmacology and experimental therapeutics, 287(1), 1998, pp. 167-186
Authors:
AUDINOT V
NEWMANTANCREDI A
GOBERT A
RIVET JM
BROCCO M
LEJEUNE F
GLUCK L
DESPOSTE I
BERVOETS K
DEKEYNE A
MILLAN MJ
Citation: V. Audinot et al., A COMPARATIVE IN-VITRO AND IN-VIVO PHARMACOLOGICAL CHARACTERIZATION OF THE NOVEL DOPAMINE D-3 RECEPTOR ANTAGONISTS (-S-14297, NAFADOTRIDE, GR-103,691 AND U-99194()), The Journal of pharmacology and experimental therapeutics, 287(1), 1998, pp. 187-197
Authors:
MILLAN MJ
SCHREIBER R
DEKEYNE A
RIVET JM
BERVOETS K
MAVRIDIS M
SEBBAN C
MAURELREMY S
NEWMANTANCREDI A
SPEDDING M
MULLER O
LAVIELLE G
BROCCO M
Citation: Mj. Millan et al., S-16924 YL]-PYRROLIDIN-3YL)-1-(4-FLUORO-PHENYL)-ETHANONE), A NOVEL, POTENTIAL ANTIPSYCHOTIC WITH MARKED SEROTONIN (5-HT)(1A) AGONIST PROPERTIES - II - FUNCTIONAL PROFILE IN COMPARISON TO CLOZAPINE AND HALOPERIDOL, The Journal of pharmacology and experimental therapeutics, 286(3), 1998, pp. 1356-1373